Form 4: Zimmer Biomet Director Arthur J. Higgins Reports Acquisition of Equity Compensation

Zimmer Biomet Holdings, Inc. Director Arthur J. Higgins reported the acquisition of phantom stock units and restricted stock units as part of his compensation on May 29, 2025.

Summary

• Arthur J. Higgins, a Director of Zimmer Biomet Holdings, Inc. (ZBH), reported changes in his beneficial ownership of derivative securities.
• On May 29, 2025, Mr. Higgins acquired 810.46 Phantom Stock Units at a value of $92.54 per unit.
• These Phantom Stock Units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The Phantom Stock Units are to be settled in cash in five annual installments, commencing within sixty days after the end of the calendar year in which Mr. Higgins' service as a Director ceases.
• The reported beneficial ownership of Phantom Stock Units following this transaction is 34,904.384 units, which includes 79.853 units accrued on April 30, 2025, under the dividend reinvestment provision of the plan.
• Also on May 29, 2025, Mr. Higgins acquired 1,404.798 Restricted Stock Units (RSUs).
• These RSUs are immediately 100% vested but are subject to mandatory deferral until the later of the reporting person's termination of service as a Director or three years after the grant date.
• The reported beneficial ownership of Restricted Stock Units following this transaction is 24,864.726 units, which includes RSUs granted in prior years subject to different mandatory deferral periods.

Sentiment

Score: 5

Explanation: The document is a routine Form 4 filing detailing director compensation. It does not contain information that would significantly alter the company's financial outlook or operational performance, thus indicating a neutral sentiment.

Positives

• The acquisition of phantom stock units and restricted stock units aligns the director's financial interests with those of the shareholders, as the value of these units is tied to the company's stock performance.
• The deferred compensation structure for non-employee directors is a common practice that can help retain experienced board members.

Future Outlook

The phantom stock units are scheduled to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the reporting person's service as a Director ceases. The Restricted Stock Units are subject to mandatory deferral until the later of the reporting person's termination of service as a Director or three years after the grant date.

Management Comments

• The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.

Industry Context

The granting of equity-based compensation, such as phantom stock units and restricted stock units, to non-employee directors is a common practice across publicly traded companies, particularly in the healthcare and medical device industry. This compensation structure is designed to align the interests of the board members with those of the shareholders by tying a portion of their remuneration to the company's stock performance.

Comparison to Industry Standards

• The use of phantom stock units and restricted stock units for director compensation is a standard practice in corporate governance, aligning with compensation strategies observed in peer companies within the medical technology sector.
• The deferral mechanisms for both phantom stock and RSUs are typical for non-employee director compensation plans, promoting long-term commitment and stewardship.

Corporate Governance

Related Party Transactions

• The acquisition of phantom stock units and restricted stock units by Arthur J. Higgins, a Director of Zimmer Biomet Holdings, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's interests with shareholder value, potentially encouraging decisions that benefit long-term stock performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Settlement of phantom stock units in cash in five annual installments commencing within sixty days after the end of the calendar year of the director's cessation of service.
• Mandatory deferral of Restricted Stock Units until the later of the director's termination of service or three years after the grant date.

Key Dates

Keywords

Zimmer Biomet, ZBH, Form 4, Insider Transaction, Equity Compensation, Phantom Stock Units, Restricted Stock Units, Director Compensation, Deferred Compensation Plan